Screener
Design Therapeutics, Inc. DSGN Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Design Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026.
- Filed
- Apr 28, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-187063
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies (See Note 8) | ||
| Stockholders’ equity: | ||
| Common stock, $0.0001 par value; 200,000,000 shares authorized at March 31, 2026 and December 31, 2025; 62,441,429 and 60,398,051 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 6 | 6 |
| Additional paid-in capital | 532,958 | 509,100 |
| Accumulated deficit | (314,642) | (297,006) |
| Accumulated other comprehensive (loss) income | (268) | 403 |
| Total stockholders’ equity | 218,054 | 212,503 |
| Total liabilities and stockholders’ equity | $230,442 | $226,203 |
Item 1. Financial Statements.
FAQ
- What is Design Therapeutics, Inc.'s total equity?
- Design Therapeutics, Inc. (DSGN) reported total equity of $218.05M in Q1 2026.
- How has Design Therapeutics, Inc.'s total equity changed year-over-year?
- Design Therapeutics, Inc.'s total equity decreased by 4.3% year-over-year, from $227.92M to $218.05M.
- What is the long-term trend for Design Therapeutics, Inc.'s total equity?
- Over 5 years (2020 to 2025), Design Therapeutics, Inc.'s total equity has grown at a 79.8% compound annual growth rate (CAGR), from -$11.32M to $212.5M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Design Therapeutics, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude